Herbert Irving Comprehensive Cancer Center
Investigator
Divaya Bhutani, MD
Phone
646-317-4805
Email
db3203@cumc.columbia.edu
Divaya Bhutani, MD, is a world-leading expert in multiple myeloma therapies and treatment strategies whose work in this field has been extensively published. As a hematologist and oncologist at NewYork-Presbyterian Lawrence Hospital, he specializes in cancer care, blood disorders, and benign hematology. He also serves as an assistant professor of medicine at Columbia University Irving Medical Center.

As an expert in myeloma, Dr. Bhutani is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. A well-respected and accomplished researcher, Dr. Bhutani has presented his work at at annual medical meetings of the American Society of Hematology and has been featured in medical journals, including Pharmacology & Therapeutics and Journal of Clinical Oncology.

Dr. Divaya Bhutani graduated from Govt. Medical College, Patiala in India. He did his Internal medicine residency at Mount Sinai School of Medicine, Bronx, NY and fellowship in Hematology and Oncology at Wayne State University and Karmanos Cancer Institute, Detroit. His prior experience includes work as an Attending Physician at Myeloma Institute of Research and Therapy at University of Arkansas for Medical Sciences, Little Rock, AR and Karmanos Cancer Institute, Wayne State University, Detroit. MI.

Clinical Studies Managed By This Investigator:
Condition Study Title
Multiple Myeloma [ CLOSED ] A study for patients with previously untreated Multiple Myeloma
Multiple Myeloma [ CLOSED ] A study for patients with multiple myeloma using study drug radium-223 dichloride
Amyloidosis [ CLOSED ] Phase 3 study of safety and efficacy of Daratumumab in combination with other drugs in treating AL Amyloidosis
Multiple Myeloma [ CLOSED ] First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma [ CLOSED ] A Study for Patients with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant
Multiple Myeloma [ CLOSED ] Study of TAK-079 and Backbone Regimens in Patients with Newly Diagnosed Multiple Myeloma
Multiple Myeloma [ CLOSED ] Study of Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma [ CLOSED ] Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (CANOVA)
Amyloidosis [ CLOSED ] A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
Amyloidosis [ CLOSED ] A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
Cancer Study of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS)
Lymphoma Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant
Multiple Myeloma Study of Isatuximab in Patients with Multiple Myeloma or Lymphoma who are Recovering from Stem Cell Transplant
Lymphoma Study of Venetoclax in Addition to Usual Treatment for Patients with Waldenstrm's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Multiple Myeloma Study of Teclistamab In Patients with Multiple Myeloma
Multiple Myeloma Study of BMS-986393 in Patients with Multiple Myeloma (MM)